More on DGNOF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.22 |
|
|||
| Open | $0.22 | ||||
| 52 Wk High | $0.05 | ||||
| 52 Wk Low | $0.02 | ||||
| Day High | $0.23 | ||||
| Day Low | $0.22 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 46,490 | ||||
- DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
- DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
- DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
- DIAGNOS Announces the Engagement of IBN
- DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
- Form D Diagnos Inc.
- DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare
- DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on December 5, 2025
- DIAGNOS appoints Philippe Couillard as board chairman
- DIAGNOS Strengthens Governance and Leadership with the Appointment of Philippe Couillard as Chairman of the Board of Directors
Entities mentioned with DGNOF
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- Twitter | View Related Stories »
- Charles Gasparino | View Related Stories »
- Show More...
